GLP-1 Market
LLY $1170.14 ▲ +0.5% NVO $39.40 ▼ -1.0% PFE $27.93 ▲ +0.7% VKTX $40.85 ▲ +35.7% KLRA $12.79 ▲ +6.7% GPCR $36.91 ▲ +0.3% RHHBY $55.56 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Lurasidone Hydrochloride

Company
Dong-Wook Kim
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Lurasidone Hydrochloride and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05480150

    Chinese Longitudinal and Systematic Study of Bioplar Disorder

    Not yet reported First Affiliated Hospital of Zhejiang University 10000 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic
    View official trial listing →
  • Recruiting NCT NCT06049953

    Maternal And Infant Antipsychotic Study

    Icahn School of Medicine at Mount Sinai 74 participants Est. completion 2028-01-01 1 site
    Other conditions: Antipsychotics, Pregnancy
    View official trial listing →
  • Completed NCT NCT00044005

    Safety and Tolerability Study of Drug to Treat Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 98 participants Est. completion 2003-11 26 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00044044

    A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 356 participants Est. completion 2003-05 34 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00088621

    A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 61 participants Est. completion 2005-10 21 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00088634

    A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 180 participants Est. completion 2004-12 22 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00549666

    A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

    Not yet reported Sumitomo Pharma America, Inc. 23 participants Est. completion 2007-12 1 site Stand-alone
    Other conditions: Pharmacokinetics
    View official trial listing →
  • Completed NCT NCT00549718

    Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 489 participants Est. completion 2010-10 48 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00615433

    Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 478 participants Est. completion 2010-01 52 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00641745

    Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 629 participants Est. completion 2010-07 73 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00711269

    Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

    Not yet reported Sumitomo Pharma Co., Ltd. 460 participants Est. completion 2010-04-27 3 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00789698

    Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 240 participants Est. completion 2011-07 65 sites Stand-alone
    Other conditions: Chronic Schizophrenia
    View official trial listing →
  • Completed NCT NCT00790192

    Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

    Not yet reported Sumitomo Pharma America, Inc. 488 participants Est. completion 2010-07 65 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00806234

    Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

    Not yet reported Johns Hopkins University 127 participants Est. completion 2014-03 4 sites
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00868452

    Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

    Not yet reported Sumitomo Pharma America, Inc. 348 participants Est. completion 2012-01 71 sites Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT00868699

    Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

    Not yet reported Sumitomo Pharma America, Inc. 505 participants Est. completion 2012-02 55 sites Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT00868959

    Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

    Not yet reported Sumitomo Pharma America, Inc. 817 participants Est. completion 2013-02 151 sites Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT01074073

    Lithium Drug-Drug Interaction Study With Lurasidone HCl

    Not yet reported Sumitomo Pharma America, Inc. 24 participants Est. completion 2008-10 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01074632

    Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

    Not yet reported Sumitomo Pharma America, Inc. 26 participants Est. completion 2009-09 2 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
    View official trial listing →
  • Completed NCT NCT01082146

    RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

    Not yet reported Sumitomo Pharma America, Inc. 6 participants Est. completion 2008-08 1 site Stand-alone
    Other conditions: Pharmacokinetics, Metabolism
    View official trial listing →
  • Completed NCT NCT01082250

    The Bioequivalence Of Two Different Lurasidone Formulations In Patients

    Not yet reported Sumitomo Pharma America, Inc. 52 participants Est. completion 2008-09 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01082263

    Midazolam Drug-Drug Interaction Study With Lurasidone HCl

    Not yet reported Sumitomo Pharma America, Inc. 24 participants Est. completion 2008-11 1 site
    Other conditions: Schizophrenia Patients
    View official trial listing →
  • Completed NCT NCT01082276

    Rifampin Drug-Drug Interaction Study With Lurasidone HCl

    Not yet reported Sumitomo Pharma America, Inc. 20 participants Est. completion 2008-08 1 site
    Other conditions: Male, Healthy Normal Subjects
    View official trial listing →
  • Completed NCT NCT01082289

    Digoxin Drug-Drug Interaction With Lurasidone HCl

    Not yet reported Sumitomo Pharma America, Inc. 24 participants Est. completion 2008-10 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01143077

    A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

    Not yet reported Sumitomo Pharma America, Inc. 244 participants Est. completion 2011-05 27 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT01143090

    A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

    Not yet reported Sumitomo Pharma America, Inc. 149 participants 27 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT01173874

    Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

    Not yet reported New York State Psychiatric Institute 120 participants Est. completion 2013-11 16 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01284517

    Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

    Not yet reported Sumitomo Pharma America, Inc. 356 participants Est. completion 2012-08 75 sites Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT01358357

    Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex

    Not yet reported Sumitomo Pharma America, Inc. 965 participants Est. completion 2015-04 105 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT01364818

    Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

    University of North Carolina, Chapel Hill 25 participants Est. completion 2014-12 1 site
    Other conditions: Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
    View official trial listing →
  • Completed NCT NCT01421134

    Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

    Not yet reported Sumitomo Pharma America, Inc. 211 participants Est. completion 2014-10 43 sites Stand-alone
    Other conditions: Major Depressive Disorder With Mixed Features
    View official trial listing →
  • Withdrawn NCT NCT01423240

    Major Depressive Disorder With Mixed Features

    Not yet reported Sumitomo Pharma America, Inc. Est. completion 2012-12 27 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01423253

    Major Depressive Disorder With Mixed Features - Extension

    Not yet reported Sumitomo Pharma America, Inc. 48 participants Est. completion 2013-10 17 sites Stand-alone
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT01431326

    Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

    Daniel Benjamin 3520 participants Est. completion 2019-11 52 sites
    Chronic kidney diseaseHeart failure Other conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Hyperaldosteronism, Hypokalemia, Hemophilia, Heavy Menstrual Bleeding, Insomnia
    View official trial listing →
  • Completed NCT NCT01435928

    PEARL Schizophrenia Maintenance

    Not yet reported Sumitomo Pharma America, Inc. 676 participants Est. completion 2013-08 75 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01485640

    Lurasidone Extended Use Study

    Not yet reported Sumitomo Pharma America, Inc. 162 participants Est. completion 2014-02 46 sites Stand-alone
    Other conditions: Schizophrenia, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01498770

    An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    Organon and Co 42 participants Est. completion 2017-12-21
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01566162

    A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 191 participants Est. completion 2013-11 63 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01569659

    High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

    Not yet reported Northwestern University 101 participants Est. completion 2015-07 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01575561

    This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

    Not yet reported Sumitomo Pharma America, Inc. 377 participants Est. completion 2015-07 71 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT01614899

    A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

    Not yet reported Sumitomo Pharma Co., Ltd. 457 participants Est. completion 2014-11-17 4 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01614912

    Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

    Not yet reported Sumitomo Pharma Co., Ltd. 284 participants Est. completion 2015-05 4 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01620060

    Lurasidone Pediatric Pharmacokinetics Study

    Not yet reported Sumitomo Pharma America, Inc. 105 participants Est. completion 2013-05 10 sites Stand-alone
    Other conditions: Schizophrenia, Autism
    View official trial listing →
  • Completed NCT NCT01731119

    Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

    Not yet reported University of North Carolina, Chapel Hill 9 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
    View official trial listing →
  • Completed NCT NCT01821378

    Lurasidone Low-Dose - High-Dose Study Study

    Not yet reported Sumitomo Pharma America, Inc. 412 participants Est. completion 2014-06 66 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01833897

    NMDA Antagonists in Bipolar Depression

    Not yet reported New York State Psychiatric Institute 8 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01911429

    Pediatric Schizophrenia Efficacy and Safety Study

    Not yet reported Sumitomo Pharma America, Inc. 327 participants Est. completion 2015-12 90 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01911442

    Lurasidone Pediatric Autism Study

    Not yet reported Sumitomo Pharma America, Inc. 150 participants Est. completion 2014-11 41 sites Stand-alone
    Other conditions: Autism
    View official trial listing →
  • Completed NCT NCT01914393

    Pediatric Open-Label Extension Study

    Not yet reported Sumitomo Pharma America, Inc. 702 participants Est. completion 2018-10-17 88 sites Stand-alone
    Other conditions: Schizophrenia, Autism, Bipolar Depression
    View official trial listing →
  • Withdrawn NCT NCT01932541

    Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

    Not yet reported Massachusetts General Hospital Est. completion 2018-07 1 site Stand-alone
    Other conditions: Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01979679

    A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

    Not yet reported University of California, Irvine 28 participants 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01986101

    A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

    Not yet reported Sumitomo Pharma Co., Ltd. 525 participants Est. completion 2017-02-16 8 sites
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT01986114

    A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

    Not yet reported Sumitomo Pharma Co., Ltd. 495 participants Est. completion 2018-02-17 8 sites
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT02002832

    A Clinical Trial of Lurasidone in Treatment of Schizophrenia

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 388 participants Est. completion 2015-11 15 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02046369

    Lurasidone Pediatric Bipolar Study

    Not yet reported Sumitomo Pharma America, Inc. 350 participants Est. completion 2016-10 66 sites Stand-alone
    Other conditions: Bipolar I Depression
    View official trial listing →
  • Completed NCT NCT02147379

    Lurasidone and Cognition in Bipolar I Disorder

    Not yet reported University of British Columbia 53 participants Est. completion 2017-01-12 1 site Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT02174510

    A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 37 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02174523

    Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 14 participants Est. completion 2014-04 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02181803

    Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

    Not yet reported Merck Sharp & Dohme LLC 55 participants Est. completion 2015-04-23 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02199743

    Lurasidone Effects on Tissue Glutamate in Schizophrenia

    Not yet reported University of Texas Southwestern Medical Center 35 participants Est. completion 2016-06 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Withdrawn NCT NCT02213887

    Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications

    Not yet reported University of British Columbia Est. completion 2020-11-02 1 site
    Other conditions: Psychotic Disorders, Gastroesophageal Reflux
    View official trial listing →
  • Completed NCT NCT02237417

    Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

    Not yet reported University of Utah 47 participants Est. completion 2020-07-30 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02239094

    Biosignatures of Latuda for Bipolar Depression

    Not yet reported New York State Psychiatric Institute 20 participants Est. completion 2016-09 1 site
    Other conditions: Bipolar Depression
    View official trial listing →
  • Status unknown NCT NCT02282085

    Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

    Not yet reported Matt Byerly 200 participants 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02435095

    Antipsychotic Induced Structural and Functional Brain Changes

    Not yet reported RWTH Aachen University 174 participants Est. completion 2020-08 11 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02731612

    Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

    Not yet reported Lakshmi N Yatham 100 participants Est. completion 2024-12-31 9 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Terminated NCT NCT02893371

    Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

    University of New Mexico 1037352 participants Est. completion 2019-06-30 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02974010

    Sequential Therapy for the Treatment of Severe Bipolar Depression.

    Not yet reported NeuroRx, Inc. 22 participants Est. completion 2019-11-20 4 sites Stand-alone
    Other conditions: Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
    View official trial listing →
  • Completed NCT NCT03304457

    Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 100 participants Est. completion 2018-03-25 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03319953

    A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

    Not yet reported Neurocrine Biosciences 23 participants Est. completion 2019-11-06 1 site Stand-alone
    Other conditions: Stable Schizophrenia
    View official trial listing →
  • Completed NCT NCT03393026

    A Study of Lurasidone HCl in Subjects With Schizophrenia

    Not yet reported Standard Chem. & Pharm. Co., Ltd. 54 participants Est. completion 2019-09-17 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03395392

    NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

    Not yet reported, Not yet reported NeuroRx, Inc. 74 participants Est. completion 2024-03-30 14 sites Stand-alone
    Other conditions: Bipolar Depression, Suicidal Ideation and Behavior
    View official trial listing →
  • Status unknown NCT NCT03396068

    NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

    Not yet reported NeuroRx, Inc. 72 participants Est. completion 2024-12-31 4 sites Stand-alone
    Other conditions: Bipolar Depression, Suicidal Ideation
    View official trial listing →
  • Completed NCT NCT03402152

    NRX101 Glx Biomarker Validation Study

    Not yet reported, Not yet reported NeuroRx, Inc. 8 participants Est. completion 2021-06-01 1 site Stand-alone
    Other conditions: Bipolar Depression, Suicidal Ideation
    View official trial listing →
  • Completed NCT NCT03465787

    A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

    Not yet reported Bukwang Pharmaceutical 210 participants Est. completion 2022-10-26 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03557931

    A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

    Not yet reported Astellas Pharma Global Development, Inc. 233 participants Est. completion 2019-10-21 27 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03565068

    A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

    Not yet reported Merck Sharp & Dohme LLC 75 participants Est. completion 2020-04-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03627195

    A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 40 participants Est. completion 2019-03-29 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03786614

    Antidepressant Discontinuation in Treatment Resistant Depression

    Not yet reported University of Louisville 30 participants Est. completion 2024-12 1 site
    Other conditions: Treatment Resistant Depression
    View official trial listing →
  • Completed NCT NCT03902613

    18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

    Not yet reported New York State Psychiatric Institute 1 participants Est. completion 2019-08-01 1 site Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT04002700

    A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

    Janssen Research & Development, LLC 1234412 participants Est. completion 2019-05-31 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT04312503

    Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    Aziende Chimiche Riunite Angelini Francesco S.p.A 95 participants Est. completion 2022-10-31 18 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT04383691

    A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 124 participants Est. completion 2022-12-23 26 sites Stand-alone
    Other conditions: Bipolar I Depression
    View official trial listing →
  • Completed NCT NCT04432688

    The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

    Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 3192 participants Est. completion 2023-06-18 7 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT04742413

    A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

    Angelini Farmacéutica 9 participants Est. completion 2022-03-15 10 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT05011669

    The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 200 participants Est. completion 2023-06-16 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT05213143

    The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 13 participants Est. completion 2022-11-18 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT05351736

    Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)

    Not yet reported Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 10 participants Est. completion 2024-04-28 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT05741502

    An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

    Not yet reported Ohio State University 5 participants Est. completion 2026-01-23 1 site
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Available NCT NCT05779267

    NRX-101 Expanded Access

    NeuroRx, Inc. 1 site
    Other conditions: Treatment-Resistant Depression
    View official trial listing →
  • Status unknown NCT NCT06128213

    NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

    Not yet reported NeuroRx, Inc. 13 participants Est. completion 2024-09-30 Stand-alone
    Other conditions: Urinary Tract Infections, Pyelonephritis
    View official trial listing →
  • Withdrawn NCT NCT06328140

    Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

    George West Mental Health Foundation d/b/a Skyland Trail Est. completion 2025-01-22 1 site
    Other conditions: Bipolar Disorder, Major Depressive Disorder, Psychosis
    View official trial listing →
  • Active, not recruiting NCT NCT06433635

    Sequential Multiple Assignment Randomized Trial for Bipolar Depression

    Not yet reported Massachusetts General Hospital 2726 participants Est. completion 2030-02-28 18 sites Stand-alone
    Other conditions: Bipolar I Disorder, Depression
    View official trial listing →
  • Completed NCT NCT06527885

    Lurasidone Non-Interventional Study in Schizophrenia Patients

    Aziende Chimiche Riunite Angelini Francesco S.p.A 61 participants Est. completion 2023-09-12 3 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Not yet recruiting NCT NCT06695676

    Effects of Lurasidone on Left Ventricle Systolic Functions

    Aydin Adnan Menderes University 62 participants Est. completion 2025-06-01 1 site
    Other conditions: Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders
    View official trial listing →
  • Not yet recruiting NCT NCT07227103

    A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

    Not yet reported, Not yet reported NeuroRx, Inc. 400 participants Est. completion 2028-03-31 3 sites Stand-alone
    Other conditions: Treatment Resistant Depression, Treatment Resistant Depression (TRD)
    View official trial listing →
  • Not yet recruiting NCT NCT07781293

    Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy

    Not yet reported Bukwang Pharmaceutical 364 participants Est. completion 2027-10 Stand-alone
    Other conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
    View official trial listing →
  • Not yet recruiting NCT NCT07785102

    Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

    Not yet reported Mclean Hospital 30 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Major Depression
    View official trial listing →
  • Not yet recruiting NCT NCT07806227

    Broadband Near Infrared Spectroscopy to Understand the Role of Brain Cytochrome C Oxidase in Bipolar Disorder

    Not yet reported Martin Lan 60 participants Est. completion 2028-07-30 1 site Stand-alone
    Other conditions: Bipolar Disorder Depression
    View official trial listing →
  • Completed NCT NCT07834112

    Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder: a Multicenter Retrospective Study of Selected Follow-up Cohort

    Dong-Wook Kim 155 participants Est. completion 2025-12-31 1 site
    Other conditions: Bipolar Disorder (BD)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Lurasidone Hydrochloride, Lurasidone

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.